Future Directions in Treatment of Chronic Lymphocytic Leukemia (CLL) with BTK Inhibitors

Bhavesh Shah, RPh, BCOP, and Ryan Jacobs, MD, share considerations for approaching an individualized treatment regimen for patients with CLL.

Dr Ryan Jacobs evaluates the use of chemotherapy options for first-line treatment of CLL.

Experts in hematology/oncology discuss goals of therapy and optimal treatment selection for patients with chronic lymphocytic leukemia.

Ryan Jacobs, MD, and Bhavesh Shah, RPh, BCOP, provide insight on considerations when choosing a BTK inhibitor for initial treatment of chronic lymphocytic leukemia.

Dr Ryan Jacobs, MD, leads a review of the phase 3 SEQUOIA trial presented at ASH 2021 evaluating the use of zanubrutinib for previously untreated CLL and discusses the management of adverse events with BTK inhibitors.

Key opinion leaders in hematology-oncology share recommendations on switching from first-generation BTK inhibitors to next-generation BTK inhibitors for the management of patients with CLL.

Ryan Jacobs, MD, and Bhavesh Shah, RPh, BCOP, comment on the role of pharmacists in clinical practice for managing patients with CLL.

Bhavesh Shah, RPh, BCOP, and Ryan Jacobs, MD, discuss emerging agents in the pipeline and the future treatment landscape for CLL.